| Field | Specification |
|---|---|
| Mfr No | |
| Activity | |
| Cas No. | |
| Concentration | |
| Form | Lyophilized Powder |
| Product Type | |
| Purity | |
| Reconstitution | |
| Shipping | |
| Solubility | 50 mM in DMSO. Centrifuge all product preparations before use (10000 x g 5 min). |
| Source | Synthetic |
| Storage | |
| Target |
Product details
- Chemical name: 6-nitro-2-[(6-nitro-1H-benzimidazol-2-yl)methoxymethyl]-1H-benzimidazole.
- CAS number: 1222810-74-3
- Molecular formula: C16H12N6O5.
- Purity: ≥99%
- Concentration: 0.1-50 µM.
- Form: Lyophilized Powder
- Solubility: 50 mM in DMSO. Centrifuge all product preparations before use (10000 x g 5 min).
- Reconstitution: 50 mM in DMSO. Centrifuge all product preparations before use (10000 x g 5 min).
- Shipping: Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.
- Target: Kir1.1 channel
- Source: Synthetic
- Activity: VU591 is a Kir1.1 channel blocker1.
Scientific background
VU591 is a potent and selective blocker of renal outer medullary potassium channel, ROMK (Kir1.1). Kir1.1 channel is a putative drug target for a novel class of loop diuretic drugs that hold the ability to lower pressure and blood volume without causing hypokalemia. VU591 seems to block the intracellular pore of the channel and does so with an IC50 of 300 nM.ROMK channels are expressed in the thick ascending limb of Henle's loop, connecting tubule, and collecting duct segments of the nephron. They mediate K+ secretion into the urinary filtrate. ROMK provides K+ ions in the thick ascending limb that are necessary for NaCl reabsorption by the Na+-K+-2Cl− cotransporter and loop diuretic target. In the connecting tubule and collecting duct, ROMK constitutes a key pathway for K+ secretion.Evidence shows that ROMK antagonists could serve as potent diuretic drugs by inhibiting Na+ reabsorption in the thick ascending limb of Henle's loop and minimizing urinary K+ ions loss in the collecting duct. Thus, administration of VU591, a direct diuretic, can avoid hypokalemia, a side effect caused from treatment of conventional loop and thiazide diuretics in cases of hypertension and congestive heart failure.
Lead time: 1-2 Business Days
Country of origin: Israel/IL
Applications key
Application key: FC- Flow cytometry, IFC- Indirect flow cytometry, IHC- Immunohistochemistry,LCI- Live cell imaging, Calcium imaging assay,Cell survival assay, Electrophysiology, Neurite outgrowth assay.
Bioassay tested: Yes
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
